OCPA joined with Do No Harm, a group of medical professionals, to defend SB 613 in an amici curiae brief filed in the case. The two groups jointly filed their latest brief with the U.S. Court of Appeals for the Tenth Circuit in support of affirmance of Heil’s denial of the preliminary injunction.
“No reliable scientific evidence justifies the use of puberty blockers, cross-sex hormones, and surgeries to treat gender dysphoria in minors,” OCPA and Do No Harm’s latest brief states. “To the contrary, such treatments carry harmful lifelong consequences, including infertility, total loss of adult sexual function, and increased risk of several other serious medical conditions. Despite activists’ efforts to stifle dissent, even otherwise sympathetic audiences have begun to raise the alarm over the use of these treatments.”
Read more on OCPA.
Get up to speed with the threats facing healthcare – and how we’re protecting patients and physicians.
"*" indicates required fields